Goud R, Lufkin B, Duffy J, et al. - Using Medicare claims data, researchers herein investigated if vaccination with the recombinant zoster vaccine (RZV) is associated with an increased risk of developing Guillain-Barré Syndrome (GBS).

• A total of 849,397 RZV-vaccinated and 1,817,099 zoster vaccine live (ZVL or Zostavax)-vaccinated beneficiaries aged 65 years or older were included in this case series cohort study.

• Between the risk and control windows, a rate ratio of 2.84 was identified following a medical record–based, self-controlled analysis of GBS cases after RZV vaccination, resulting in an attributable risk of 3 cases per million RZV (Shingrix) doses.

• Overall findings suggest that risk of developing GBS increases following vaccination with RZV.